Diverse small molecule heterocyclic compound libraries for drug discovery
A curated collection of small molecule heterocycles (MW ~200-500) including novel substituted isoxazoles, quinolinones, pyrazoles, furans, and butenolides, designed using innovative synthetic methodology to engage biological targets in oncology, infectious diseases, and pain therapeutics.
Overview
This offering provides access to a diverse, proprietary collection of small molecule heterocyclic compound libraries spanning molecular weights of approximately 200-500 daltons. The libraries encompass novel substituted isoxazoles, quinolinones, pyrazoles, furans, and butenolides, all developed through innovative synthetic methodology discovered by the research team. These compounds have been designed to engage a variety of biological targets and have been applied across ongoing medicinal chemistry programs in oncology, infectious diseases, and pain therapeutics.
The collection is distinguished by the inclusion of validated pharmacophores known to possess biological activity, combined with unprecedented control of regioselectivity and chemoselectivity during synthesis. This makes the libraries particularly valuable for pharmaceutical and biotechnology partners seeking novel chemical matter for drug discovery programs.
Technical specifications
Compound classes available:
- Substituted isoxazoles – novel scaffolds with validated pharmacophores
- Quinolinones – diverse substitutions targeting biological activity
- Pyrazoles – designed for engagement with therapeutic targets
- Furans – novel heterocyclic structures
- Butenolides – unique chemical entities for medicinal chemistry
Key features:
- Molecular weight range of approximately 200-500 daltons
- Compounds built on validated pharmacophores with known biological activity
- Synthesis achieved with unprecedented regioselectivity and chemoselectivity control
- Developed as part of active medicinal chemistry programs in oncology, infectious diseases, and pain
- Based on novel synthetic methodology discovered by the research team
Technology readiness level
The compound libraries have been developed and synthesized using new synthetic methodology, with ongoing medicinal chemistry programs in multiple therapeutic areas including oncology, infectious diseases, and pain. The compounds incorporate validated pharmacophores, indicating established biological relevance. The libraries are available for collaborative research, licensing, or co-development partnerships with industry partners seeking novel chemical matter for drug discovery.
About University of Texas, San Antonio
The University of Texas at San Antonio (UTSA) is a comprehensive public research university and federally designated Hispanic‑Serving Institution recognized with Carnegie R1 status. Industry collaboration is anchored by a downtown presence that co‑locates the School of Data Science with the National Security Collaboration Center, enabling shared labs, secure environments, and close interaction with government and corporate partners. The university’s location within San Antonio’s defense and aerospace ecosystem—including a formal collaboration with Port San Antonio—provides access to testbeds, talent pipelines, and dual‑use development pathways. Research is supported by competitive federal funding from major national agencies. A dedicated technology transfer office advances IP strategy, licensing, and startup formation for industry‑ready solutions.
delivered to your inbox.